The microbiome of kidney stones and urine of patients with nephrolithiasis
Urolithiasis · 04.01.2023 · 51 (1)
DOI: 10.1007/s00240-022-01403-5 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Urolithiasis, online erschienen am 04.01.2023. Verfasst von Ursula Lemberger und 8 weiteren Autor:innen. Beteiligte Einrichtung: Research Laboratory, Department of Urology, Medical University of Vienna, Waeringerguertel 18-20, 1090, Vienna, Austria. ursula.lemberger@meduniwien.…. Hauptthemen laut MEDLINE: Metabolic Syndrome, Kidney Calculi, Nephrolithiasis, Microbiota. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Vienna.
Abstract (Originalsprache)
The incidence of nephrolithiasis is rising worldwide. Although it is a multifactorial disease, lifestyle plays a major role in its etiology. Another considerable factor could be an aberrant microbiome. In our observational single-center study, we aimed to investigate the composition of bacteria in kidney stones and urine focusing on patients with features of metabolic syndrome. Catheterized urine and kidney stones were collected prospectively from 100 consecutive patients undergoing endoscopic nephrolithotomy between 2020 and 2021 at our clinic. Microbiome composition was analyzed via 16S rRNA gene amplicon sequencing. Detection of bacteria was successful in 24% of the analyzed kidney stones. These patients had a prolonged length of stay compared to patients without verifiable bacteria in their stones (2.9 vs 1.5 days). Patients with features of metabolic syndrome were characterized by kidney stones colonized with classical gastrointestinal bacteria and displayed a significant enrichment of Enterococcaceae and Enterobacteriaceae. Stones of patients without features of metabolic syndrome characterized by Ureaplasma and Staphylococcaceae . Patients with bacteria in their kidney stones exhibit a longer length of stay, possibly due to more complex care. Patients presenting with features of metabolic syndrome displayed a distinct stone microbiome compared to metabolically fit patients. Understanding the role of bacteria in stone formation could enable targeted therapy, prevention of post-operative complications and new therapeutic strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research Laboratory, Department of Urology, Medical University of Vienna, Waeringerguertel 18-20, 1090, Vienna, Austria. ursula.lemberger@meduniwien.ac.at.
- Joint Microbiome Facility of the Medical University of Vienna and the University of Vienna, Vienna, Austria.
- Division of Microbial Ecology, Department of Microbiology and Ecosystem Science, Centre for Microbiology and Environmental Systems Science, University of Vienna, Vienna, Austria.
- Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.
- Research Laboratory, Department of Urology, Medical University of Vienna, Waeringerguertel 18-20, 1090, Vienna, Austria.
- Departments of Urology, Weill Cornell Medical College, New York, USA.
Förderung
- Medical University of Vienna
Zitieren
APA
Lemberger, U., Pjevac, P., Hausmann, B., Berry, D., Moser, D., Jahrreis, V., Özsoy, M., Shariat, S. F., & Veser, J. (2023). The microbiome of kidney stones and urine of patients with nephrolithiasis. Urolithiasis, 51(1). https://doi.org/10.1007/s00240-022-01403-5
Vancouver
Lemberger U, Pjevac P, Hausmann B, Berry D, Moser D, Jahrreis V, et al. The microbiome of kidney stones and urine of patients with nephrolithiasis. Urolithiasis. 2023;51(1). doi:10.1007/s00240-022-01403-5
BibTeX
@article{Lemberger2023,
author = {Lemberger, Ursula and Pjevac, Petra and Hausmann, Bela and Berry, David and Moser, Daniel and Jahrreis, Victoria and Özsoy, Mehmet and Shariat, Shahrokh F and Veser, Julian},
title = {The microbiome of kidney stones and urine of patients with nephrolithiasis},
journal = {Urolithiasis},
year = {2023},
volume = {51},
number = {1},
doi = {10.1007/s00240-022-01403-5}
}
EUVIMED